Neukio Biotherapeutics

company

About

Neukio Biotherapeutics is a developer of allogenic immune cell therapies for treatment of cancer.

Details

Last Funding Type
Series A
Last Funding Money Raised
$50M
Industries
Biotechnology
Founded date
Jan 1, 2021
Operating Status
Active

Neukio Biotherapeutics is an immune cell drug developer, focusing on the research and development and industrialization of immune cell drugs, developing iPSC-CAR-NK general-purpose spot immune cell products, and is committed to providing effective therapeutic drugs for cancer patients around the world.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$90M
Neukio Biotherapeutics has raised a total of $90M in funding over 2 rounds. Their latest funding was raised on Sep 2, 2022 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 2, 2022 Series A $50M 3 Detail
Jul 29, 2021 Angel $40M 1 Lilly Asia Ventures Detail

Investors

Number of Lead Investors
Number of Investors
1
3
Neukio Biotherapeutics is funded by 3 investors. Yahui Precision Medicine Fund and Kuanyu Private Equity are the most recent investors.
Investor Name Lead Investor Funding Round
Yahui Precision Medicine Fund Series A
Kuanyu Private Equity Series A
Lilly Asia Ventures Series A